Moberg Pharma Annual report for 2023
Moberg Pharma´s Annual report for 2023 has been published and is available on www.mobergpharma.se
For additional information, please contact:
Anna Ljung, VD, phone: +46 707 66 6030, e-mail: [email protected]
Mark Beveridge, CFO, phone: +46 76 805 82 88, e-mail: [email protected]
About this information
This information is information that Moberg Pharma AB (publ.) is obliged to make public in accordance with the Securities Market Act. The information was submitted for publication, through the contact persons set out above at 08.00 p.m CET on April 12, 2024.
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis, for which market approvals in several EU-countries has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).
